Apogenix Ag

Apogenix Gmbh

Abbvie Inc.

Oliver Hill

Christian Gieffers

Meinolf Thiemann

Tim Schnyder

Marcus Branschädel

Marcus Branschaedel

Marcus Branschadel

Harald Fricke

Jaromir Sykora

Christian Merz

Susan E Lappe

Darren C Phillips

Matilde Todaro

Giorgio Stassi

Carmen Fischer

Fritz G Buchanan

Marcus BRANSCHÄDEL

Christian Giffers

Christian Giefffers

The present invention refers to single-chain fusion proteins comprising three soluble TNF superfamily (TNFSF) cytokine domains and nucleic acid molecules encoding these fusion proteins. The fusion proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.

Light single-chain fusion polypeptides, encoding nucleic acid molecules and host cells

Provided herein are specific GITR receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a GITRL-associated disease or disorder. The GITR receptor agonist proteins provided herein comprise three soluble GITRL domains and an Fc fragment. The GITR receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.

Single-chain glucocorticoid-induced tumor necrosis factor receptor (GITR) receptor agonist proteins

The present invention relates to a specific CD95L antibody and to the use thereof in the treatment or diagnosis of diseases involving CD95L-induced signalling, e.g. cancer diseases.

Monoclonal anti-CD95L (cluster of differentiation 95 ligand) antibody

Provided herein are specific CD137 receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a CD137L-associated disease or disorder. The CD137 receptor agonist proteins provided herein comprise three soluble CD137L domains and an Fe fragment. The CD137 receptor agonist proteins are substantially non-aggregating and suitable for therapeuctic, diagnostic and/or research applications.

Single-chain CD137-receptor agonist proteins

Provided herein are specific CD27 receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a CD27L-associated disease or disorder. The CD27 receptor agonist proteins provided herein comprise three soluble CD27L domains an and Fc fragment. The CD27 receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.

Single-chain CD27-receptor agonist proteins

Provided herein are specific CD40 receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a CD40L-associated disease or disorder. The CD40 receptor agonist proteins provided herein comprise three soluble CD40L domains and an Fc fragment. The CD40 receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.

Single-chain CD40-receptor agonist proteins

Provided herein are specific TL1A receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a TL1A-associated disease or disorder. The TL1A receptor agonist proteins provided herein comprise three soluble TL1A domains and an Fc fragment. The TL1A receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.

Single-chain TL1A receptor agonist proteins

Provided herein are specific LIGHT receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a LIGHT-associated disease or disorder. The LIGHT receptor agonist proteins provided herein comprise three soluble LIGHT domains and an Fc fragment. The LIGHT receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.

Single-chain light receptor agonist proteins

CD27 ligand (CD27L) single-chain fusion polypeptides

Single-chain glucocorticoid-induced tumor necrosis factor receptor (GITR) agonist proteins

The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof. The fusion protein, the nucleic acid, and the cell is suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications.

CD27L collectin fusion proteins and encoding nucleic acids

CD40L single-chain fusion polypeptides and encoding nucleic acids

Monoclonal anti-CD95L antibody

The present invention relates to an isolated fusion protein comprising an extracellular CD95 domain or a functional fragment thereof and an Fc domain or functional fragment thereof, formulations providing such fusion protein in a stable form as well as a method for producing such a fusion protein.

Growing community of inventors

Neckarsteinach, Germany

Oliver Hill